Sichenzia Ross Ference LLP Represents Inmune Bio, Inc. in a $40.0 Million Registered Direct Offering
![Sichenzia Ross Ference LLP Represents Inmune Bio, Inc. in a $40.0 Million Registered Direct Offering inmunebio logo](https://srfc.law/wp-content/uploads/2019/02/inmunelogo-150x42.png)
Press Release – New York, New York – July 16, 2021 – Sichenzia Ross Ference LLP announced today that it represented Inmune Bio, Inc. (Nasdaq: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in a registered direct offering of common stock at a purchase price of $22.00 per share with two institutional investor. The gross proceeds from the offering were $40.0 million.
A.G.P./Alliance Global Partners acted as sole placement agent for the offering.
The Sichenzia Ross Ference LLP team was led by partners Marc Ross, Thomas Rose and Barrett DiPaolo.
- Sichenzia Ross Ference Carmel LLP represents Calidi Biotherapeutics, Inc. in $4.25 Million Public Offering - January 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents Craft Capital Management LLC and Boustead Securities, LLC in $5 Million Initial Public Offering of Class A Ordinary Shares of 3 E Network Technology Group Limited - January 13, 2025
- Sichenzia Ross Ference Carmel LLP Name Sharon Carroll and Devin Heck as Partners - January 8, 2025